p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22)

Leuk Res. 2004 Jan;28(1):97-9. doi: 10.1016/s0145-2126(03)00161-9.

Abstract

The simultaneous occurrence of two specific primary chromosomal changes in hematological malignancies is rare. We report on a patient with acute myelo-monocytic leukemia and both inv(16)(p13q22) and t(9;22)(q34;q11) with a p190(BCR-ABL) rearrangement. The t(9;22)(q34;q11) translocation appears to be a secondary change. Similar secondary BCR-ABL rearrangements have already been described and, in most cases, the chimeric protein was of the p190(BCR-ABL) type as in our case. A complete remission was obtained by conventional chemotherapy followed with imatinib mesylate maintenance therapy. At relapse, the BCR-ABL transcripts were undetectable, which suggests that imatinib mesylate could be an effective adjuvant treatment in acute leukemia with a secondary t(9;22)(q34;q11).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Chromosomes, Human, Pair 22 / genetics*
  • Chromosomes, Human, Pair 9 / genetics*
  • Cytogenetics
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Gene Rearrangement
  • Humans
  • Imatinib Mesylate
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Monocytic, Acute / etiology
  • Leukemia, Monocytic, Acute / genetics*
  • Piperazines / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use
  • Remission Induction
  • Salvage Therapy
  • Translocation, Genetic

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl